CoChat
Sign Up
Cited by 45

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation

Mizukawa, Benjamin, O’Brien, Eric, Moreira, Daniel C., Wunderlich, Mark, Hochstetler, Cindy L., Duan, Xin, Liu, Wei, Orr, Emily, Grimes, H. Leighton, Mulloy, James C., Zheng, Yi·2017·Blood
DOI 10.1182/blood-2016-12-758458
Open this paper in CoChat — free account

Abstract

Key Points: CDC42 regulates AML cell polarity and division symmetry. CDC42 suppression in AML cells promotes differentiation and blocks leukemia progression.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2016-12-758458

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 3 references

Research works printed but not linked: 37

  1. Yang, 2007, Rho GTPase Cdc42 coordinates hematopoietic stem cell quiescence and niche interaction in the bone marrow, Proc Natl Acad Sci USA, 104, 5091, 10.1073/pnas.0610819104 · DOI
  2. Wang, 2006, Genetic deletion of Cdc42GAP reveals a role of Cdc42 in erythropoiesis and hematopoietic stem/progenitor cell survival, adhesion, and engraftment, Blood, 107, 98, 10.1182/blood-2005-05-2171 · DOI
  3. Somervaille, 2006, Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia, Cancer Cell, 10, 257, 10.1016/j.ccr.2006.08.020 · DOI · Paper page
  4. Wei, 2008, Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia, Cancer Cell, 13, 483, 10.1016/j.ccr.2008.04.020 · DOI · Paper page
  5. Majeti, 2009, Dysregulated gene expression networks in human acute myelogenous leukemia stem cells, Proc Natl Acad Sci USA, 106, 3396, 10.1073/pnas.0900089106 · DOI · Paper page
  6. Bajaj, 2015, Fearful symmetry: subversion of asymmetric division in cancer development and progression, Cancer Res, 75, 792, 10.1158/0008-5472.CAN-14-2750 · DOI
  7. Ito, 2010, Regulation of myeloid leukaemia by the cell-fate determinant Musashi, Nature, 466, 765, 10.1038/nature09171 · DOI
  8. Wu, 2007, Imaging hematopoietic precursor division in real time, Cell Stem Cell, 1, 541, 10.1016/j.stem.2007.08.009 · DOI
  9. Ito, 2012, A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance, Nat Med, 18, 1350, 10.1038/nm.2882 · DOI
  10. Yamamoto, 2013, Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells, Cell, 154, 1112, 10.1016/j.cell.2013.08.007 · DOI
  11. Yang, 2006, Gene targeting of Cdc42 and Cdc42GAP affirms the critical involvement of Cdc42 in filopodia induction, directed migration, and proliferation in primary mouse embryonic fibroblasts, Mol Biol Cell, 17, 4675, 10.1091/mbc.e06-05-0466 · DOI
  12. Goyama, 2013, Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells, J Clin Invest, 123, 3876, 10.1172/JCI68557 · DOI
  13. Wunderlich, 2010, AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3, Leukemia, 24, 1785, 10.1038/leu.2010.158 · DOI · Paper page
  14. Zuber, 2011, Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi, Nat Biotechnol, 29, 79, 10.1038/nbt.1720 · DOI
  15. Bagger, 2016, BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis, Nucleic Acids Res, 44, D917, 10.1093/nar/gkv1101 · DOI · Paper page
  16. Corral, 1996, An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes, Cell, 85, 853, 10.1016/S0092-8674(00)81269-6 · DOI
  17. Tanaka, 2012, Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia, Blood, 120, 1107, 10.1182/blood-2011-11-394932 · DOI
  18. Price, 1998, Activation of Rac and Cdc42 by integrins mediates cell spreading, Mol Biol Cell, 9, 1863, 10.1091/mbc.9.7.1863 · DOI
  19. Etienne-Manneville, 2004, Cdc42--the centre of polarity, J Cell Sci, 117, 1291, 10.1242/jcs.01115 · DOI
  20. Szczur, 2009, The small Rho GTPase Cdc42 regulates neutrophil polarity via CD11b integrin signaling, Blood, 114, 4527, 10.1182/blood-2008-12-195164 · DOI
  21. Lavau, 1997, Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL, EMBO J, 16, 4226, 10.1093/emboj/16.14.4226 · DOI
  22. Dick, 2008, Stem cell concepts renew cancer research, Blood, 112, 4793, 10.1182/blood-2008-08-077941 · DOI
  23. Lane, 2009, The leukemic stem cell niche: current concepts and therapeutic opportunities, Blood, 114, 1150, 10.1182/blood-2009-01-202606 · DOI
  24. Konopleva, 2011, Leukemia stem cells and microenvironment: biology and therapeutic targeting, J Clin Oncol, 29, 591, 10.1200/JCO.2010.31.0904 · DOI
  25. Ishikawa, 2007, Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region, Nat Biotechnol, 25, 1315, 10.1038/nbt1350 · DOI · Paper page
  26. Saito, 2010, Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML, Nat Biotechnol, 28, 275, 10.1038/nbt.1607 · DOI
  27. Saito, 2010, Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells, Sci Transl Med, 2, 17ra9, 10.1126/scitranslmed.3000349 · DOI
  28. Yang, 2007, Cdc42: a signal coordinator in hematopoietic stem cell maintenance, Cell Cycle, 6, 1444, 10.4161/cc.6.12.4371 · DOI
  29. Kawahara, 2012, H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia, Cancer Cell, 22, 194, 10.1016/j.ccr.2012.06.027 · DOI
  30. Pandolfi, 2015, PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome, Blood, 126, 1118, 10.1182/blood-2014-12-618801 · DOI
  31. Hawkins, 2008, Upsides and downsides to polarity and asymmetric cell division in leukemia, Oncogene, 27, 7003, 10.1038/onc.2008.350 · DOI
  32. Zimdahl, 2014, Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia, Nat Genet, 46, 245, 10.1038/ng.2889 · DOI
  33. Pham, 2014, Polarized cells, polarized views: asymmetric cell division in hematopoietic cells, Front Immunol, 5, 26, 10.3389/fimmu.2014.00026 · DOI
  34. Will, 2013, Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment, Nat Immunol, 14, 437, 10.1038/ni.2572 · DOI
  35. Roeder, 2006, Asymmetry of stem cell fate and the potential impact of the niche: observations, simulations, and interpretations, Stem Cell Rev, 2, 171, 10.1007/s12015-006-0045-4 · DOI
  36. Friesland, 2013, Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility, Proc Natl Acad Sci USA, 110, 1261, 10.1073/pnas.1116051110 · DOI
  37. Zins, 2013, Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activity, J Transl Med, 11, 295, 10.1186/1479-5876-11-295 · DOI

Cited by

Metadata

Authors
Mizukawa, B., O’Brien, E., Moreira, D. C., Wunderlich, M., Hochstetler, C. L., Duan, X., Liu, W., Orr, E., Grimes, H. L., Mulloy, J. C., & Zheng, Y.
Affiliations
  • Division of Oncology,
  • Division of Experimental Hematology and Cancer Biology, and
  • Division of Immunobiology, Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
ORCID
Grimes, H. Leighton
Venue
Blood
Publisher
American Society of Hematology
Published
2017-09-14
Volume
130
Issue
11
Pages
1336-1346
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2016-12-758458
Cited by
45
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review